ABSTRACT
Drug discovery is a lengthy and costly process where it normally takes a range of 11-13 years for a final drug to be approved and released in the market. During this journey, pharmacology, toxicity profile, clinical and preclinical studies take place.1,2
With the rise of artificial intelligence (AI), machine learning and computer-aided drug design (CADD), it appears that these developments have advanced and expedited the process of hits identification and discovery of lead compounds for the drug to go through the discovery phases.1,2
AIDDISON™ Empowers medicinal chemists by streamlining the entire drug discovery process. Leveraging generative AI and advanced CADD methods, AIDDISON™ integrates ligand-based and structure-based approaches into a single, easy-to-use platform. it provides all the tools needed to move from idea to actionable insight with greater efficiency and confidence.3
SYNTHIA™ Retrosynthesis Software is expert-coded by chemists and engineered by computer scientists, it enables scientists to quickly find and easily navigate innovative and novel pathways for novel and published target molecules.4
In addition to in-silico development, some important in-vitro screening methods have made it possible to screen up to billions of molecules against a drug target in a single afternoon.5
- S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg, et al., How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nat. Rev. Drug Discov. 9 (3) (2010) 203–214.
- L. Sleire, H.E. Førde, I.A. Netland, L. Leiss, B.S. Skeie, P.Ø. Enger. Drug repurposing in cancer Pharmacol. Res., 124 (2017), pp. 74-91
- https://www.sigmaaldrich.com/SA/en/services/software-and-digital-platforms/aiddison-ai-powered-drug discovery?msockid=096fe5c0be1b63c422d8f1f8bff462f8
- https://www.merckgroup.com/en/news/aiddison-drug-discovery-software-05-12-2023.html
- https://www.synthiaonline.com/
- https://www.sigmaaldrich.com/SA/en/product/sial/dyna002?msockid=096fe5c0be1b63c422d8f1f8bff462f8
Bio (MOHAMMAD IBRAHIM):
A chemist with PhD degree in organic chemistry, with research interests and publication record in:
- Organic synthesis of bioactive natural compounds.
- Materials engineering and bionanocomposites.
Currently working for Merck KGaA as Academia Segment Manager-Middle East, with responsibility to enhance collaboration with the research and academic communities in the middle east region.
Worked before as
- Division manager -Mass Spec & Nanotechnology (Naizak Global Engineering Systems)-KSA
- Chemist (Royal Scientific Society)-Jordan
- Teacher assistant (Jordan Univ. Of Science & Technology)-Jordan